Core Viewpoint - Company Ayhuilong (688575.SH) is entering the rapidly growing brain-computer interface (BCI) sector through a strategic partnership with Shenzhen Brain Machine Starlink Technology Co., Ltd, which has raised concerns from the stock exchange regarding the feasibility and details of this collaboration [1][2][3] Group 1: Partnership Details - Ayhuilong signed a strategic cooperation framework agreement with Brain Machine Starlink to integrate BCI technology with clinical and market resources for product development and market expansion [1][2] - Brain Machine Starlink, established in September 2025 with a registered capital of 5 million yuan, focuses on comprehensive diagnosis, treatment, and rehabilitation of brain diseases, with several products still in early development stages [3][4] - Ayhuilong holds a 4% indirect stake in Brain Machine Starlink, which is currently developing non-invasive technology products, distinguishing it from Neuralink's invasive approach [4] Group 2: Exchange Inquiries - The Shanghai Stock Exchange issued a rapid inquiry to Ayhuilong, requesting detailed disclosures on the commercial viability of Brain Machine Starlink, the feasibility of collaborative R&D, and the potential for future investments [2][5][6] - The first inquiry focuses on the commercial rationale of Brain Machine Starlink, including its technology routes, product types, and development status, as well as the timeline for future agreements and revenue sharing [4][5] - The second inquiry addresses the feasibility of collaborative R&D, asking for details on ongoing projects, expected investments, and the timeline for signing specific agreements [5][6] - The third inquiry concerns the feasibility of future investments, requesting specifics on potential equity investments or funding support for Brain Machine Starlink [6] Group 3: Financial Performance - Ayhuilong's core business involves the development, production, and sales of in vitro diagnostic instruments and related reagents, with a significant market presence in hospitals [7] - The company experienced a dramatic increase in revenue and net profit in 2022, attributed to sales growth in both non-COVID and COVID-related products, but has since faced a decline in performance [8] - From 2023 to 2025, Ayhuilong's revenue and net profit have shown consecutive declines, with a reported net profit of 60.42 million yuan in the first three quarters of 2025, down 72.36% year-on-year [8][9] - As of September 2025, Ayhuilong's cash flow has significantly decreased, with a net cash flow of 64.99 million yuan, and total receivables and inventory amounting to 1.171 billion yuan [9][10]

Core Insights - The brain-computer interface (BCI) sector is gaining significant attention in the A-share market, with a notable surge in stock prices since January 5, 2026, leading to a cumulative increase of approximately 18% over three trading days [1][3] - Experts predict that 2026 will be a pivotal year for the commercialization of BCI technology, driven by advancements in technology, influx of capital, and market expectations [1] Market Performance - The human brain engineering sector experienced a cumulative increase of 17.98% over the first three trading days of 2026 [3] - Notable stocks such as Innovation Medical and Nanjing Panda have achieved consecutive trading limits, with Innovation Medical's stock price reaching 28.63 yuan per share on January 7, 2026 [4][3] Key Developments - Elon Musk's Neuralink plans to begin large-scale production of BCI devices in 2026, transitioning to a more streamlined and automated surgical process [3] - Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking it as the second-largest financing in the BCI sector after Neuralink [3] Company Insights - Innovation Medical holds a 68.36% stake in Bole Brain Technology, which is involved in the medical-grade BCI rehabilitation sector [4] - Meihua Medical, a leading global supplier of cochlear implants, is exploring synergies between invasive BCI products and cochlear implant technologies [4] Technology Landscape - BCI technology is categorized into three main types: invasive, semi-invasive, and non-invasive, each with distinct advantages and challenges [6] - Invasive BCIs, like those developed by Neuralink, offer high precision but come with significant surgical risks [6] - Non-invasive BCIs are more accessible and cost-effective but face limitations in signal resolution [6] Policy and Industry Outlook - The Ministry of Industry and Information Technology has set ambitious goals for the BCI industry, aiming to cultivate globally influential companies and a competitive ecosystem by 2030 [7] - Current challenges in BCI commercialization include high-precision neural signal decoding, safety of invasive devices, and ethical considerations [7] Commercialization Challenges - Many companies, including Weisi Medical and Sanbo Brain Science, have indicated that their BCI products are still in the early stages of market development and have not yet achieved significant sales [8] - The market is witnessing speculative investments, with some companies lacking substantial technology or products, leading to potential valuation bubbles [9] Evaluation Criteria - Companies in the BCI sector should be assessed based on their technological barriers, clinical and commercialization capabilities, and overall financial health [10]

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Insights - Neuralink is set to begin large-scale production in 2026, transitioning to a more streamlined and fully automated surgical process [7] - The brain-computer interface (BCI) market is projected to reach approximately $3.19 billion by 2025, with significant growth expected in medical applications, potentially reaching $40 billion by 2030 and $145 billion by 2040 [9] - The Chinese BCI market is anticipated to exceed 3.8 billion yuan by 2025, with a compound annual growth rate of around 20% [10] - The report emphasizes the strong demand in the medical sector, particularly for spinal cord injury rehabilitation, and the increasing interest in consumer electronics and industrial applications [10] Summary by Sections Industry Performance - The computer industry has shown a relative performance of 5.7% over the last month, -3.9% over the last three months, and 33.3% over the last year, outperforming the CSI 300 index [5] Investment Highlights - Neuralink aims to achieve full human-AI connectivity through its three product lines, with plans to increase electrode counts significantly by 2028 [8] - The report identifies key applications such as telepathy for motor function disorders, blindsight for visual reconstruction, and deep brain stimulation for neurological conditions [9] Policy and Technological Support - The Chinese government has established a comprehensive support system for the BCI industry, with initiatives aimed at fostering innovation and establishing a competitive ecosystem by 2030 [11] - Significant technological advancements have been made in the BCI field, including successful clinical trials and innovations in both invasive and non-invasive technologies [12] Related Companies - The report highlights several companies that are expected to benefit from the growth in the BCI sector, including Yanshan Technology, Entropy Technology, and others [12]

Core Viewpoint - Neuralink is set to begin mass production of brain-machine interface devices in 2026, transitioning to a streamlined and nearly fully automated surgical process [1][19]. Group 1: Company Overview - Neuralink was founded in 2016 with the goal of enabling direct control of computers through neural signals via a coin-sized brain chip [4]. - The company focuses on treating neurological disorders such as paralysis, muscular atrophy, Parkinson's disease, Alzheimer's, and vision impairments [4]. - As of September 2025, Neuralink had served only 12 patients, which raises questions about the pace of its clinical applications despite significant market demand [2][18]. Group 2: Technological Advancements - The upcoming surgical procedure will simplify the implantation of brain chips by allowing electrode wires to penetrate the dura mater without the need for surgical removal, reducing complexity and risk [2][20]. - This new "minimally invasive" approach is expected to lower costs, risks, and recovery times, making the procedure more standardized and accessible [2][20]. Group 3: Clinical Trials and Milestones - The first human trial participant, Noland Arbaugh, was implanted with a Neuralink device in January 2024, enabling him to post on social media and play video games using only his thoughts [4][16]. - By December 2025, the number of participants in clinical trials had increased to 20, indicating a gradual acceleration in the pace of trials [18]. Group 4: Future Implications - Elon Musk envisions Neuralink not only as a medical device but also as a means for humanity to keep pace with potential advanced artificial intelligence, suggesting that brain-machine interfaces could enhance human capabilities [6][7]. - The potential for widespread adoption of brain-machine interfaces could lead to significant advancements in human progress, allowing for skills to be updated like software [7].

2026年二级市场的第一个热门概念属于脑机接口。 板块3日涨幅17.98% 新年伊始，脑机接口概念股集体沸腾，2026年以来的3个交易日里，人脑工程板块累计涨幅达到17.98%。 消息面上，马斯克近日表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进行大规模生产，并转向更加精简和几乎完全自动化的外科手术流 程。此外，据报道，脑机接口"独角兽"强脑科技近期完成约20亿元融资，为脑机接口领域除Neuralink以外世界第二大规模融资，进一步点燃投资者热情。 在上述消息影响下，1月5日—6日，人脑工程板块掀起涨停潮，多只个股连续两个交易日"20cm"涨停。1月7日，美好医疗再度"20cm"涨停，南京熊猫、岩山 科技等个股斩获三连板。爱朋医疗、麦澜德、伟思医疗等个股则出现回调，其中爱朋医疗跌逾11%。 自1月5日起，A股人脑工程板块"起飞"，1月5日—6日，板块内个股掀起涨停潮。1月7日，尽管板块内部分个股出现回调，但板块3日涨幅仍接近18%，创新 医疗、南京熊猫等多只概念股斩获三连板。 股价狂飙背后，脑机接口，这一曾只存在于科幻作品中的概念，正在加速走进现实。在业内专家看来，2026年有望成为 ...

Core Viewpoint - Aihui Long (688575.SH) announced a strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd. to explore brain-computer interface technology, which has raised regulatory concerns due to the sudden nature of the announcement and the company's recent poor performance in its core business [2][3][5]. Group 1: Company Announcement and Market Reaction - Aihui Long signed a strategic cooperation framework agreement with Brain Machine Starlink on January 6, focusing on brain-computer interface technology development and commercialization [2]. - Following the announcement, Aihui Long's stock price surged from 14.64 CNY to 15.80 CNY, marking a 6.52% increase with a trading volume up by 299% compared to the previous day [2]. - The Shanghai Stock Exchange issued an inquiry to Aihui Long regarding the feasibility of the cooperation, including questions about the partnership's rationale and potential insider trading [2][5]. Group 2: Financial Performance and Concerns - Aihui Long's financial performance has been declining, with a 7.69% drop in revenue and a 72.36% decrease in net profit for the first three quarters of 2025 [3][6]. - The company is attempting to pivot into the growing brain-computer interface market amid stagnation in its core business of in vitro diagnostic instruments [3]. - The inquiry from the exchange also focused on the reasons behind the significant decline in Aihui Long's financials and the potential impact of the new cooperation on its existing business [6]. Group 3: Details on the Cooperation Partner - Brain Machine Starlink was established only four months prior to the announcement, with a registered capital of 5 million CNY and a focus on comprehensive diagnosis, treatment, and rehabilitation of brain diseases [3][4]. - Both companies share the same registered address in Shenzhen, raising questions about the legitimacy and depth of the partnership [4]. - The products under development by Brain Machine Starlink, including non-invasive brain-computer interface devices, are still in early stages and have not yet entered the registration phase [4].

分析师及联系人 [Table_Author] 行业研究丨点评报告丨软件与服务 [Table_Title] Neuralink 将开启大规模量产，脑机接口产业商 业化落地有望加速 报告要点 [Table_Summary] 北京时间 1 月 1 日上午，埃隆・马斯克在社交媒体 X 上表示，其脑机接口公司 Neuralink 今年 将开始实现"大规模生产"脑机接口设备，并转向更精简、几乎完全自动化的外科手术流程。 当前时点，以 Neuralink 为代表的脑机接口产业正通过技术突破推动其商业化进展。在其规模 化量产预期和技术突破的催化下，脑机接口产业商业化落地有望加速，惠及全产业链。建议关 注三条主线：1、侵入式脑机接口海外先进产业链的国内映射标的；2、非侵入式脑机接口在消 费场景的产品落地相关标的；3、脑机接口下游应用端相关标的。 宗建树 陈耀文 SAC：S0490520030004 SAC：S0490525070002 SFC：BUX668 丨证券研究报告丨 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 软件与服务 cjzqdt11111 [Table_Titl ...

Core Insights - The article highlights the significant stock price increase of Sanbo Neurosurgery, driven by developments in the brain-computer interface (BCI) sector, particularly following Elon Musk's announcement regarding Neuralink's plans for mass production of BCI devices by 2026 [1][3][4]. Company Performance - Sanbo Neurosurgery's stock price rose to 93.82 yuan per share, marking a 10.45% increase on January 7, 2026, with a cumulative increase of 59.07% since the beginning of the year [1][3]. - The stock reached a peak of 100 yuan per share during trading, reflecting a 17.72% intraday increase [3]. Major Shareholder Insights - TBP3Doctors (HK) Limited, the largest shareholder of Sanbo Neurosurgery, acquired approximately 30.465 million shares at 4.44 yuan per share in December 2015, totaling an investment of 135 million yuan [1][6]. - TBP has since recouped its initial investment through partial share sales, with a current holding valued at approximately 2.834 billion yuan, resulting in a total profit of about 2.885 billion yuan, yielding a return of over 21 times [1][6][7]. Investment Background - TBP is controlled by Li Shujun, founder of Zhi Xin Capital, which manages over 8 billion USD and has invested in notable companies such as Douban and Haier [2][7]. - Li Shujun has a history of successful investments, preferring to acquire significant equity stakes in early-stage companies and later exiting through public offerings [8][9]. Industry Developments - The BCI sector is gaining traction, with Sanbo Neurosurgery being recognized as a leading player due to its strong capabilities in neurosurgery [3][4]. - Recent advancements include the successful completion of the world's first invasive BCI trial in China, which restored motor function in a paralyzed patient [4]. Strategic Investments - Sanbo Neurosurgery is actively investing in the BCI space, committing 87 million yuan to acquire a 29% stake in a venture capital fund focused on brain science tools and early-stage companies in neurological and psychiatric disorders [5]. - Additional investments include 10 million yuan for an 11.11% stake in another fund targeting medical devices for brain disease diagnosis and treatment [5].

Group 1 - Neuralink plans to start mass production of brain-machine interface devices in 2026 with a nearly fully automated surgical process [1] - The announcement led to a surge in A-share brain-machine interface stocks from January 5 to January 6, followed by a pullback on January 7 [1] - Nanjing Panda stated that it has no mature products related to brain-machine interfaces and that the concept will not materially impact its current operations [1] Group 2 - Plittech announced that its LCP film products, suitable for flexible electrode materials in brain-machine interfaces, are seeing positive market prospects as the industry matures [2] - Plittech is the only domestic company capable of large-scale production of LCP film technology and is currently conducting clinical trials with overseas clients [2] - Yachuang Electronics mentioned its subsidiary's membership in the brain-machine interface industry alliance and its application of AFE96× chips in EEG and EMG detection [2] Group 3 - Hansan Technology is monitoring developments in the brain-machine interface field and may enter the market in the future, although it currently focuses on smart audio applications [3]

2026年A股开门红，脑机接口相关概念股均迎来暴涨。 自1月5日开始，三博脑科（301293）、翔宇医疗、美好医疗（301363）、伟思医疗、诚益通（300430） 等股票连续多个交易日出现20%涨停，冠昊生物（300238）、塞力医疗（603716）、创新医疗 （002173）、南京熊猫（600775）、岩山科技（002195）等也都连续10%涨停。截至1月7日记者发稿， 脑机接口板块依然涨停不断。 多重利好消息传来 消息面上，埃隆.马斯克近日表示，旗下脑机接口公司Neuralink将于2026年开始大规模生产脑机接口设 备，并将同步推进流程高度精简、几乎完全自动化的外科手术方案。这一表态更是引发脑机接口相关概 念股热度快速攀升。有消息称，量产后，脑机单台植入手术的成本将从百万美元降至10万美元以内，全 自动化落地后有望进一步下探至5万美元区间，为日后脑机接口设备的大规模商业化埋下伏笔。 国内政策层面，2025年7月，工业和信息化部、国家发展改革委、教育部、国家卫生健康委、国务院国 资委、中国科学院、国家药监局七部门联合印发《关于推动脑机接口产业创新发展的实施意见》（以下 简称《意见》），首次系统性地明确了 ...